Hormone, Bone Health and Cholesterol Balance
Soy and its major components daidzein and genistein, has estrogenic effects and can acts as an estrogen-modulator in both men and women. Soy also has cholesterol-lowering, antioxidant and anti-cancer effects.
Soy has been shown to:
- lower the risk of cardiovascular disease
(a health claim allowed by the FDA) 24-27 - exert anti-cancer effects (may help prevent and even treat cancer, especially breast and prostate cancer) 10-23
- lower cholesterol levels 1-9
- increase bone density and decrease bone mineral loss 28-33
- improve insulin sensitivity 34-35
- improve menopausal symptoms 36-40
- possess antioxidant properties 41-45
Soy may therefore be useful in:
- Cancer prevention and treatment
- Heart disease
- High cholesterol
- Menopause symptoms
- Osteoporosis prevention and treatment
Allergy to soy can cause bowel gas and discomfort; raw soy products may inhibit thyroid function. In sensitive individuals, the benefits of soy may be obtained and the GI effects avoided by using the purified soy capsules.
Soy Extract (Isoflavone-250) Soy Isoflavones Benefit Both Women & Men
Beneficial substances in soy, (isoflavones, diadzen, and genisteins) have been shown to lower cholesterol levels, normalize male and female hormone balance, and prevent cancer. Soy is also used in the treatment of cancer, especially prostate and some types of breast cancers. (Physician guidance highly recommended here as soy can increase hormone levels when this is not desired).
Suggested dose: 1cap, once or twice per day with a meal. Higher doses may be used if needed to relieve menopausal hot flashes or as recommended by a physician for treatment of cancer or cholesterol levels.
References:
1.) Xiao CW, Mei J, Wood CM. Effect of soy proteins and isoflavones on lipid
metabolism and involved gene expression. Front Biosci. 2008 Jan
1;13:2660-73.
2.) Taku K, Umegaki K, Sato Y, Taki Y, Endoh K, Watanabe S. Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr. 2007 Apr;85(4):1148-56.
3.) Torres N, Torre-Villalvazo I, Tovar AR. Regulation of lipid metabolism by
soy protein and its implication in diseases mediated by lipid disorders. J
Nutr Biochem. 2006 Jun;17(6):365-73. Epub 2005 Dec 5.
4.) Zhan S, Ho SC. Meta-analysis of the effects of soy protein containing
isoflavones on the lipid profile. Am J Clin Nutr. 2005 Feb;81(2):397-408.
5.) Zhuo XG, Melby MK, Watanabe S. Soy isoflavone intake lowers serum LDL
cholesterol: a meta-analysis of 8 randomized controlled trials in humans. J
Nutr. 2004 Sep;134(9):2395-400.
6.) Dalais FS, Ebeling PR, Kotsopoulos D, McGrath BP, Teede HJ. The effects of soy protein containing isoflavones on lipids and indices of bone resorption in postmenopausal women. Clin Endocrinol (Oxf). 2003 Jun;58(6):704-9.
7.) Tonstad S, Smerud K, Høie L. A comparison of the effects of 2 doses of soy protein or casein on serum lipids, serum lipoproteins, and plasma total
homocysteine in hypercholesterolemic subjects. Am J Clin Nutr. 2002
Jul;76(1):78-84.
8.) Wangen KE, Duncan AM, Xu X, Kurzer MS. Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemic postmenopausal women. Am J Clin Nutr. 2001 Feb;73(2):225-31.
9.) Teixeira SR, Potter SM, Weigel R, et al. Effects of feeding 4 levels of soy
protein for 3 and 6 wk on blood lipids and apolipoproteins in moderately
hypercholesterolemic men. Am J Clin Nutr 2000;71:1077–84.
10.) Pendleton JM, Tan WW, Anai S, Chang M, Hou W, Shiverick KT, Rosser CJ. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer. 2008 May 11;8:132.
11.) Banerjee S, Li Y, Wang Z, Sarkar FH. Multi-targeted therapy of cancer by
genistein. Cancer Lett. 2008 May 18. [Epub ahead of
print].[###antioxidant###]
12.) Subbiah U, Raghunathan M. Chemoprotective action of resveratrol and genistein from apoptosis induced in human peripheral blood lymphocytes. J Biomol Struct Dyn. 2008 Feb;25(4):425-34.
13.) Kampkötter A, Wiegand C, Timpel C, Röhrdanz E, Chovolou Y, Kahl R, Wätjen W. Increased expression of catalase in human hepatoma cells by the soy isoflavone, daidzein. Basic Clin Pharmacol Toxicol. 2008 May;102(5):437-42. Epub 2007 Nov 28.
14.) Vaishampayan U, Hussain M, Banerjee M, Seren S, Sarkar FH, Fontana J, Forman JD, Cher ML, Powell I, Pontes JE, Kucuk O. Lycopene and soy isoflavones in the treatment of prostate cancer. Nutr Cancer. 2007;59(1):1-7.
15.) Sarkar FH, Adsule S, Padhye S, Kulkarni S, Li Y. The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini
Rev Med Chem. 2006 Apr;6(4):401-7.
16.) Kumar NB, Cantor A, Allen K, Riccardi D, Besterman-Dahan K, Seigne J, Helal M, Salup R, Pow-Sang J. The specific role of isoflavones in reducing prostate cancer risk. Prostate. 2004 May 1;59(2):141-7.
17.) Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S; Japan Public Health Center-Based Prospective Study on Cancer Cardiovascular Diseases Group. Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst. 2003 Jun 18;95(12):906-13.
18.) Sarkar FH, Li Y. Soy isoflavones and cancer prevention. Cancer Invest.
2003;21(5):744-57.
19.) Hussain M, Banerjee M, Sarkar FH, Djuric Z, Pollak MN, Doerge D, Fontana J, Chinni S, Davis J, Forman J, Wood DP, Kucuk O. Soy isoflavones in the treatment of prostate cancer. Nutr Cancer. 2003;47(2):111-7.
20.) Sarkar FH, Li Y. Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer Metastasis Rev. 2002;21(3-4):265-80.
21.) Lamartiniere CA, Cotroneo MS, Fritz WA, Wang J, Mentor-Marcel R, Elgavish A. Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate. J Nutr. 2002 Mar;132(3):552S-558S.
22.) Lamartiniere CA. Protection against breast cancer with genistein: a
component of soy. Am J Clin Nutr. 2000 Jun;71(6 Suppl):1705S-7S; discussion 1708S-9S.
23.) Messina MJ, Persky V, Setchell KD, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994;21:113–31.
24.) Rimbach G, Boesch-Saadatmandi C, Frank J, Fuchs D, Wenzel U, Daniel H, Hall WL, Weinberg PD. Dietary isoflavones in the prevention of cardiovascular disease–a molecular perspective. Food Chem Toxicol. 2008 Apr;46(4):1308-19. Epub 2007 Jul 3.
25.) Clair RS, Anthony M. Soy, isoflavones and atherosclerosis. Handb Exp
Pharmacol. 2005;(170):301-23.
26.) Cassidy A, de Pascual Teresa S, Rimbach G. Molecular mechanisms by which dietary isoflavones potentially prevent atherosclerosis. Expert Rev Mol Med. 2003 Sep 30;5(24):1-15.
27.) Clarkson TB. Soy, soy phytoestrogens and cardiovascular disease. J Nutr.2002 Mar;132(3):566S-569S.
28.) Ma DF, Qin LQ, Wang PY, Katoh R. Soy isoflavone intake increases bone mineral density in the spine of menopausal women: meta-analysis of
randomized controlled trials. Clin Nutr. 2008 Feb;27(1):57-64. Epub 2007 Dec
11.
29.) Harkness LS, Fiedler K, Sehgal AR, Oravec D, Lerner E. Decreased bone
resorption with soy isoflavone supplementation in postmenopausal women. J
Womens Health (Larchmt). 2004 Nov;13(9):1000-7.
30.) Messina M, Ho S, Alekel DL. Skeletal benefits of soy isoflavones: a review of the clinical trial and epidemiologic data. Curr Opin Clin Nutr Metab
Care. 2004 Nov;7(6):649-58.
31.) Chen YM, Ho SC, Lam SS, Ho SS, Woo JL. Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial. J Clin Endocrinol Metab. 2003 Oct;88(10):4740-7.
32.) Messina M, Messina V. Soyfoods, soybean isoflavones, and bone health: a brief overview. J Ren Nutr. 2000 Apr;10(2):63-8.
33.) Alekel DL, Germain AS, Peterson CT, Hanson KB, Stewart JW, Toda T.
Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine
of perimenopausal women. Am J Clin Nutr. 2000 Sep;72(3):844-52.
34.) Cederroth CR, Vinciguerra M, Gjinovci A, Kühne F, Klein M, et al. Dietary
phytoestrogens activate AMP-activated protein kinase with improvement in
lipid and glucose metabolism. Diabetes. 2008 May;57(5):1176-85. Epub 2008
Apr 16.
35.) Nordentoft I, Jeppesen PB, Hong J, Abudula R, Hermansen K. Increased Insulin Sensitivity and Changes in the Expression Profile of Key Insulin Regulatory Genes and Beta Cell Transcription Factors in Diabetic KKAy-Mice after Feeding with a Soy Bean Protein Rich Diet High in Isoflavone Content. J Agric Food Chem. 2008 Jun 4. [Epub ahead of print]
36.) Cheng G, Wilczek B, Warner M, Gustafsson JA, Landgren BM. Isoflavone
treatment for acute menopausal symptoms. Menopause. 2007 May-Jun;14(3 Pt 1):468-73.
37.) Nahas EA, Nahas-Neto J, Orsatti FL, Carvalho EP, Oliveira ML, Dias R.
Efficacy and safety of a soy isoflavone extract in postmenopausal women: a
randomized, double-blind, and placebo-controlled study. Maturitas. 2007 Nov
20;58(3):249-58. Epub 2007 Oct 29.
38.) McCarty MF. Isoflavones made simple – genistein’s agonist activity for the
beta-type estrogen receptor mediates their health benefits. Med Hypotheses.
2006;66(6):1093-114. Epub 2006 Mar 2.
39.) Messina M, Hughes C. Efficacy of soyfoods and soybean isoflavone supplements for alleviating menopausal symptoms is positively related to initial hot flush frequency. J Med Food. 2003 Spring;6(1):1-11.
40.) Burke GL, Legault C, Anthony M, Bland DR, Morgan TM, Naughton MJ, Leggett K, Washburn SA, Vitolins MZ. Soy protein and isoflavone effects on vasomotor symptoms in peri- and postmenopausal women: the Soy Estrogen Alternative Study. Menopause. 2003 Mar-Apr;10(2):147-53.
41.) Bertipaglia de Santana M, Mandarino MG, et al. Association between soy and
green tea (Camellia sinensis) diminishes hypercholesterolemia and increases
total plasma antioxidant potential in dyslipidemic subjects. Nutrition. 2008
Jun;24(6):562-8.
42.) Kim NY, Song EJ, Kwon DY, Kim HP, Heo MY. Antioxidant and antigenotoxic activities of Korean fermented soybean. Food Chem Toxicol. 2008 Mar;46(3):1184-9. Epub 2007 Dec 8.
43.) Hämäläinen M, Nieminen R, Vuorela P, Heinonen M, Moilanen E. Anti-inflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kappaB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-kappaB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediators Inflamm. 2007;2007:45673.
44.) Hu CC, Hsiao CH, Huang SY, Fu SH, Lai CC, Hong TM, Chen HH, Lu FJ. Antioxidant activity of fermented soybean extract. J Agric Food Chem. 2004 Sep 8;52(18):5735-9.
45.) Cai Q, Rahn RO, Zhang R. Dietary flavonoids, quercetin, luteolin and genistein, reduce oxidative DNA damage and lipid peroxidation and quench free radicals. Cancer Lett. 1997 Oct 28;119(1):99-107.
